羟氯喹联合泼尼松治疗风湿免疫系统疾病的临床疗效对照研究

蒋雪玲

[摘要] 目的 探析羥氯喹联合泼尼松治疗风湿免疫系统疾病的临床疗效。方法 方便选取2017年5月—2019年5月在该院接受治疗的109例风湿免疫系统疾病患者予以分组研究，随机分为对照组（n=54）与研究组（n=55）。对照组患者给予泼尼松治疗，研究组患者给予羟氯喹联合泼尼松治疗，比较两组患者临床疗效、不良反应发生率、关节肿胀指数及疼痛指数。结果 对照组患者临床总有效率为81.48%，研究组患者为94.55%，研究组显著高于对照组（χ2=4.427，P<0.05）。对照组患者不良反应发生率为7.41%，研究组患者为9.09%，数据比较差异无统计学意义（χ2=0.102，P>0.05）。治疗前，对照组患者关节肿胀指数、疼痛指数分别为（3.82±0.95）分、（3.50±0.84）分，研究组患者分别为（3.81±0.93）分、（3.52±0.81）分，数据比较差异无统计学意义（t=0.120、0.220，P>0.05）;治疗后，对照组患者关节肿胀指数、疼痛指数分别为（1.77±0.51）分、（1.71±0.37）分，研究组患者分别为（0.68±0.42）分、（0.66±0.31）分，研究组显著低于对照组（t=6.540、6.820，P<0.05）。结论 风湿免疫系统疾病患者应用羟氯喹联合泼尼松治疗的效果更加确切，能够显著改善患者关节肿胀与疼痛症状，且未明显增加不良反应。

[关键词] 风湿免疫系统疾病;羟氯喹;泼尼松;临床疗效

[中图分类号] R593          [文献标识码] A          [文章编号] 1674-0742（2020）07（b）-0098-03

[Abstract] Objective To explore the clinical efficacy of hydroxychloroquine combined with prednisone in the treatment of rheumatic immune system diseases. Methods 109 patients with rheumatic immune system disease who were treated in the hospital from May 2017 to May 2019 were convenient selected for group study and randomly divided into a control group （n=54） and a research group（n=55）. Patients in the control group were treated with prednisone， and patients in the study group were treated with hydroxychloroquine combined with prednisone. The clinical efficacy， incidence of adverse reactions， joint swelling index and pain index were compared between the two groups. Results The total clinical effective rate was 81.48% in the control group and 94.55% in the study group. The study group was significantly higher than the control group （χ2= 4.427， P<0.05）. The incidence of adverse reactions in the control group was 7.41%， and that in the study group was 9.09%. The data was not statistically significantly different （χ2=0.102， P>0.05）. Before treatment， the joint swelling index and pain index of the control group were （3.82±0.95） points and （3.50±0.84） points respectively， while those of the study group were （3.81±0.93） points and （3.52±0.81） points respectively，which difference was not statistically significant （t=0.120， 0.220， P>0.05）; after treatment， the joint swelling index and pain index of the control group were （1.77±0.51） points and （1.71±0.37） points respectively， and the study group patients were （0.68±0.42） points and （0.66±0.31） points， the study group was statistically significantly lower than the control group （t=6.540， 6.820， P<0.05）. Conclusion The effect of hydroxychloroquine combined with prednisone in patients with rheumatic immune system disease is more accurate. It can significantly improve the joint swelling and pain symptoms of patients， and does not significantly increase adverse reactions.